Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review summarizes NCCN guidelines for prostate cancer early detection, focusing on strategies to maximize detection of potentially curable cases while minimizing unnecessary procedures, but it reports no new clinical findings.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that low-dose tamoxifen may effectively treat painful gynecomastia in patients receiving flutamide and finasteride for advanced prostate cancer.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.

This study observed that circulating testosterone affects baseline sex differences in voiding function in C57BL/6J mice, with prostate lobe mass having a lesser impact.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This study identifies SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive prostate cancer, indicating its role in tumor invasion and growth.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This study indicated that while testosterone replacement in older men with low testosterone increases muscle mass and strength and reduces fat, its effects on physical function, disability, falls, or fractures remain unclear.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.

Both drugs lower DHT levels, with GI198745 being more effective.

This review discusses the association between androgen receptor CAG repeat polymorphism and several health conditions, including Kennedy’s disease and urologic disorders, without reporting new clinical results.

This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.

This review discusses the clinical use of anti-androgen medications and highlights emerging evidence supporting plant-derived anti-androgens like spearmint tea for managing PCOS, but reports no new clinical results.

This study reported that women with PCOS had higher levels of certain hormones and lower SHBG levels compared to non-PCOS women with similar symptoms, highlighting a less favorable endocrine profile in PCOS cases.

The study observed that finasteride reduced fertility in male Sprague-Dawley rats by impairing the formation of copulatory plugs, an effect considered specific to rats and not applicable to species without this reproductive feature.